MCTA

Charming Medical Limited
CAPPED RATING

Charming Medical Limited (MCTA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Value (D-). The rating has held at C for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
D-
Factor Score 0.8 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 419.4
EV / EBITDA 1.5K
Rev Growth YoY -18.9%
Gross Margin 96.4%
Price Return 3M 0.0%
Price Return 12M 0.0%
Catalyst Signal 0.00
Market Cap $445.6M
TTM Revenue $4.8M
Price / Sales 92.7
ROE -0.9%

Historical Factor Score Progression

Held C for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 D- (0.8) D- (0.9) B+ (3.8) B- (3.0) C+ (2.6) C (2.2)
2026-11-06 D- (0.8) D- (0.9) B+ (3.8) B- (3.1) C+ (2.7) C (2.3)
2026-10-30 D- (0.8) D- (0.9) B+ (3.8) B- (3.0) C+ (2.7) C (2.2)
2026-10-23 D- (0.8) D- (0.9) B+ (3.8) C+ (2.5) C+ (2.6) C- (2.1)
2026-10-16 D- (0.8) D- (0.9) B+ (3.8) C+ (2.5) C+ (2.6) C- (2.1)
Page 1 of 4